103 results on '"Pain models"'
Search Results
2. Mouse models of surgical and neuropathic pain produce distinct functional alterations to prodynorphin expressing neurons in the prelimbic cortex
- Author
-
Shudi Zhou, Yuexi Yin, and Patrick L. Sheets
- Subjects
Pain models ,Prodynorphin ,Electrophysiology ,Brain slice ,Prelimbic cortex ,Sex differences ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
The medial prefrontal cortex (mPFC) consists of a heterogeneous population of neurons that respond to painful stimuli, and our understanding of how different pain models alter these specific mPFC cell types remains incomplete. A distinct subpopulation of mPFC neurons express prodynorphin (Pdyn+), the endogenous peptide agonist for kappa opioid receptors (KORs). Here, we used whole cell patch clamp for studying excitability changes to Pdyn expressing neurons in the prelimbic region of the mPFC (PLPdyn+ neurons) in mouse models of surgical and neuropathic pain. Our recordings revealed that PLPdyn+ neurons consist of both pyramidal and inhibitory cell types. We find that the plantar incision model (PIM) of surgical pain increases intrinsic excitability only in pyramidal PLPdyn+ neurons one day after incision. Following recovery from incision, excitability of pyramidal PLPdyn+ neurons did not differ between male PIM and sham mice, but was decreased in PIM female mice. Moreover, the excitability of inhibitory PLPdyn+ neurons was increased in male PIM mice, but was with no difference between female sham and PIM mice. In the spared nerve injury model (SNI), pyramidal PLPdyn+ neurons were hyperexcitable at both 3 days and 14 days after SNI. However, inhibitory PLPdyn+ neurons were hypoexcitable at 3 days but hyperexcitable at 14 days after SNI. Our findings suggest different subtypes of PLPdyn+ neurons manifest distinct alterations in the development of different pain modalities and are regulated by surgical pain in a sex-specific manner. Our study provides information on a specific neuronal population that is affected by surgical and neuropathic pain.
- Published
- 2023
- Full Text
- View/download PDF
3. The role of high‐conductance calcium‐activated potassium channel in headache and migraine pathophysiology.
- Author
-
Al‐Karagholi, Mohammad Al‐Mahdi, Hakbilen, Cemile Ceren, and Ashina, Messoud
- Subjects
- *
CALCIUM-dependent potassium channels , *MIGRAINE , *SPREADING cortical depression , *ION channels , *MEDICAL research , *PATHOLOGICAL physiology , *POTASSIUM channels - Abstract
Migraine is a common, neurovascular headache disorder with a complex molecular interplay. The involvement of ion channels in the pathogenesis of migraine gathered considerable attention with the findings that different ion channels subfamilies are expressed in trigeminovascular system, the physiological substrate of migraine pain, and several ion channel openers investigated in clinical trials with diverse primary endpoints caused headache as a frequent side effect. High‐conductance (big) calcium‐activated potassium (BKCa) channel is expressed in the cranial arteries and the trigeminal pain pathway. Recent clinical research revealed that infusion of BKCa channel opener MaxiPost caused vasodilation, headache and migraine attack. Thus, BKCa channel is involved in pathophysiological mechanisms underlying headache and migraine, and targeting BKCa channel presents a new potential strategy for migraine treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. The Strategy of the Brain to Maintain the Force Production in Painful Contractions—A Motor Units Pool Reorganization.
- Author
-
Becker, Klaus, Goethel, Márcio, Fonseca, Pedro, Vilas-Boas, João Paulo, and Ervilha, Ulysses
- Subjects
- *
MOTOR unit , *HYPERTONIC solutions , *ACTION potentials , *NEUROMUSCULAR diseases , *SALINE solutions , *HUMAN mechanics - Abstract
A common symptom in neuromuscular diseases is pain, which changes human movement in many ways. Using the decomposed electromyographic signal, we investigate the strategy of the brain in recruiting different pools of motor units (MUs) to produce torque during induced muscle pain in terms of firing rate (FR), recruitment threshold (RT) and action potential amplitude (MUAPAMP). These properties were used to define two groups (G1/G2) based on a K-means clusterization method. A 2.0 mL intramuscular hypertonic (6%) or isotonic (0.9%) saline solution was injected to induce pain or act as a placebo during isometric and isokinetic knee extension contractions. While isometric torque decreases after pain induction with hypertonic solution, this does not occur in isokinetic torque. This occurs because the MUs re-organized after the injection of both solutions. This is supported by an increase in RT, in both G1 and G2 MUs. However, when inducing pain with the hypertonic solution, RT increase is exacerbated. In this condition, FR also decreases, while MUAPAMP increases only for G1 MUs. Therefore, this study proposes that the strategy for maintaining force production during pain is to recruit MUs with higher RT and MUAPAMP. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Transcutaneous Electrical Nerve Stimulation in Rodent Models of Neuropathic Pain: A Meta-Analysis.
- Author
-
Huang, Jiapeng, Yang, Chunlan, Zhao, Kehong, Zhao, Ziqi, Chen, Yin, Wang, Tingting, and Qu, Yun
- Subjects
TRANSCUTANEOUS electrical nerve stimulation ,NEURALGIA - Abstract
Transcutaneous electrical nerve stimulation (TENS) is a non-invasive therapeutic intervention that is typically used for many years to treat chronic pain in patients who are refractory to pain medications. However, evidence of the efficacy of TENS treatment for neuropathic pain is lacking in humans. To further understand the efficacy of TENS under various intervention conditions and illuminate the current circumstance and future research directions, we systematically reviewed animal studies investigating the efficacy of TENS in relieving pain in neuropathic pain rodent models. We searched the Cochrane Library, EMBASE, MEDLINE (via PubMed), and Web of Science and identified 11 studies. Two meta-analyses were performed. The first meta-analysis showed that a single TENS treatment was capable of temporarily ameliorating neuropathic pain when compared to control groups with a significant effect (standardized mean difference: 1.54; 95% CI: 0.65, 2.42; p = 0.0007; I
2 = 58%). Significant temporary alleviation in neuropathic pain intensity was also observed in the meta-analysis of repetitive TENS (standardized mean difference: 0.85; 95% CI: 0.31, 1.40; p = 0.002; I2 = 75%). Subgroup analysis showed no effect of the timing of the application of TENS (test for subgroup difference, p = 0.47). Leave-one-out sensitivity analyses suggested that no single study had an outsized effect on the pooled estimates, which may partly prove the robustness of these findings. Other stratified analyses were prevented by the insufficient number of included studies. Overall, current data suggest that TENS might be a promising therapy to ameliorate neuropathic pain. However, the high risk of bias in the included studies suggests that cautions must be considered when interpreting these findings and it is not reasonable to directly generalize the results obtained from animal studies to clinical practice. Future studies should pay more attention to improving the quality of study design and reporting, thereby facilitating the understanding of mechanisms underlying TENS treatment, reducing more potentially unsuccessful clinical trials, and optimizing the efficacy of TENS for people with neuropathic pain. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
6. Transcutaneous Electrical Nerve Stimulation in Rodent Models of Neuropathic Pain: A Meta-Analysis
- Author
-
Jiapeng Huang, Chunlan Yang, Kehong Zhao, Ziqi Zhao, Yin Chen, Tingting Wang, and Yun Qu
- Subjects
transcutaneous electrical nerve stimulation ,neuropathic pain ,animal studies ,pain models ,meta-analysis ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Transcutaneous electrical nerve stimulation (TENS) is a non-invasive therapeutic intervention that is typically used for many years to treat chronic pain in patients who are refractory to pain medications. However, evidence of the efficacy of TENS treatment for neuropathic pain is lacking in humans. To further understand the efficacy of TENS under various intervention conditions and illuminate the current circumstance and future research directions, we systematically reviewed animal studies investigating the efficacy of TENS in relieving pain in neuropathic pain rodent models. We searched the Cochrane Library, EMBASE, MEDLINE (via PubMed), and Web of Science and identified 11 studies. Two meta-analyses were performed. The first meta-analysis showed that a single TENS treatment was capable of temporarily ameliorating neuropathic pain when compared to control groups with a significant effect (standardized mean difference: 1.54; 95% CI: 0.65, 2.42; p = 0.0007; I2 = 58%). Significant temporary alleviation in neuropathic pain intensity was also observed in the meta-analysis of repetitive TENS (standardized mean difference: 0.85; 95% CI: 0.31, 1.40; p = 0.002; I2 = 75%). Subgroup analysis showed no effect of the timing of the application of TENS (test for subgroup difference, p = 0.47). Leave-one-out sensitivity analyses suggested that no single study had an outsized effect on the pooled estimates, which may partly prove the robustness of these findings. Other stratified analyses were prevented by the insufficient number of included studies. Overall, current data suggest that TENS might be a promising therapy to ameliorate neuropathic pain. However, the high risk of bias in the included studies suggests that cautions must be considered when interpreting these findings and it is not reasonable to directly generalize the results obtained from animal studies to clinical practice. Future studies should pay more attention to improving the quality of study design and reporting, thereby facilitating the understanding of mechanisms underlying TENS treatment, reducing more potentially unsuccessful clinical trials, and optimizing the efficacy of TENS for people with neuropathic pain.
- Published
- 2022
- Full Text
- View/download PDF
7. The Strategy of the Brain to Maintain the Force Production in Painful Contractions—A Motor Units Pool Reorganization
- Author
-
Klaus Becker, Márcio Goethel, Pedro Fonseca, João Paulo Vilas-Boas, and Ulysses Ervilha
- Subjects
experimental pain ,hypertonic saline ,motor unit ,muscle ,pain models ,Cytology ,QH573-671 - Abstract
A common symptom in neuromuscular diseases is pain, which changes human movement in many ways. Using the decomposed electromyographic signal, we investigate the strategy of the brain in recruiting different pools of motor units (MUs) to produce torque during induced muscle pain in terms of firing rate (FR), recruitment threshold (RT) and action potential amplitude (MUAPAMP). These properties were used to define two groups (G1/G2) based on a K-means clusterization method. A 2.0 mL intramuscular hypertonic (6%) or isotonic (0.9%) saline solution was injected to induce pain or act as a placebo during isometric and isokinetic knee extension contractions. While isometric torque decreases after pain induction with hypertonic solution, this does not occur in isokinetic torque. This occurs because the MUs re-organized after the injection of both solutions. This is supported by an increase in RT, in both G1 and G2 MUs. However, when inducing pain with the hypertonic solution, RT increase is exacerbated. In this condition, FR also decreases, while MUAPAMP increases only for G1 MUs. Therefore, this study proposes that the strategy for maintaining force production during pain is to recruit MUs with higher RT and MUAPAMP.
- Published
- 2022
- Full Text
- View/download PDF
8. Efficacy of ketamine in relieving neuropathic pain: a systematic review and meta-analysis of animal studies.
- Author
-
van Velzen, Monique, Dahan, Jack D. C., van Dorp, Eveline L. A., Mogil, Jeffrey S., Hooijmans, Carlijn R., Dahan, Albert, and Velzen, Monique van
- Subjects
- *
RESEARCH , *META-analysis , *NEURALGIA , *ANIMAL experimentation , *RESEARCH methodology , *SYSTEMATIC reviews , *MEDICAL cooperation , *EVALUATION research , *RATS , *COMPARATIVE studies , *KETAMINE , *HYPERALGESIA , *MICE - Abstract
Abstract: In humans, proof of long-term efficacy of ketamine treatment in neuropathic pain is lacking. To improve our understanding of ketamine behavior under various administration conditions, we performed a systematic review and meta-analyses of controlled studies on the efficacy of ketamine in mice and rats with a disease model of nerve injury on relief of allodynia. Searches in PubMed and EMBASE identified 31 unique studies. Four meta-analyses were conducted. The first analysis included 19 comparisons on a single ketamine dose and measurement of effect within 3 hours of dosing and showed an appreciable effect (standardized mean difference 1.6, 95% confidence interval 1.1-2.1). Subgroup analyses showed no effect of species, administration route, or dose. A single administration was insufficient to sustain relief of allodynia at 24 or 72 hours after dosing, as observed in our second analysis (7 comparisons) with similar effects in ketamine-treated and control animals. Chronic ketamine administration (9 comparisons) caused profound relief of allodynia when tested during ketamine exposure (effect size 5.1, 3.7-6.5). The final analysis (6 comparisons) showed that chronic administration caused a slow loss of relief of allodynia with 70% loss of effect 24 days after end of treatment. No subgroups analyses were possible in the last 3 meta-analyses due to small group sizes. These results indicate long-term ketamine anti-allodynic effects after chronic exposure (>3 days) but not after a single administration. Given several limitations, extrapolation of the animal data to the human condition is tenuous. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. Neuropathic pain: Spotlighting anatomy, experimental models, mechanisms, and therapeutic aspects.
- Author
-
Kankowski, Svenja, Grothe, Claudia, Haastert‐Talini, Kirsten, and Barrot, Michel
- Subjects
- *
NEURALGIA , *THERAPEUTICS , *PAIN measurement , *CENTRAL nervous system , *PAIN clinics - Abstract
The International Association for the Study of Pain defines neuropathic pain as "pain arising as a direct consequence of a lesion or disease affecting the somatosensory system". The associated changes can be observed in the peripheral as well as the central nervous system. The available literature discusses a wide variety of causes as predisposing for the development and amplification of neuropathic pain. Further, key interactions within sensory pathways have been discovered, but no common molecular mechanism leading to neuropathic pain has been identified until now. In the first part of this review, the pain mediating lateral spinothalamic tract is described. Different in vivo models are presented that allow studying trauma‐, chemotherapy‐, virus‐, and diabetes‐induced neuropathic pain in rodents. We furthermore discuss approaches to assess neuropathic pain in these models. Second, the current knowledge about cellular and molecular mechanisms suggested to underlie the development of neuropathic pain is presented and discussed. A summary of established therapies that are already applied in the clinic and novel, promising approaches closes the paper. In conclusion, the established animal models are able to emulate the diversity of neuropathic pain observed in the clinics. However, the assessment of neuropathic pain in the presented in vivo models should be improved. The determination of common molecular markers with suitable in vitro models would simplify the assessment of neuropathic pain in vivo. This would furthermore provide insights into common molecular mechanisms of the disease and establish a basis to search for satisfying therapeutic approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Understanding Women's Responses to Sexual Pain After Female Genital Cutting: An Integrative Psychological Pain Response Model.
- Author
-
Connor, Jennifer Jo, Brady, Sonya S., Chaisson, Nicole, Mohamed, Fatima Sharif, and Robinson, Beatrice "Bean" E.
- Subjects
- *
FEMALE genital mutilation , *WOMEN'S health , *WOMEN refugees , *PAIN , *WOMEN immigrants - Abstract
The World Health Organization estimates that over 200 million women and girls have experienced female genital cutting (FGC). Many women and girls who have undergone FGC have migrated to areas of the world where providers are unfamiliar with the health needs associated with FGC. Both providers in Western healthcare systems and female immigrant and refugee patients report communication difficulties leading to distrust of providers by women who have experienced FGC. Sexual pain is one common problem requiring discussion with healthcare providers and possible intervention. Yet, existing clinical and research literature provides little guidance for assessment and intervention when sexual pain is a result of FGC. Several conceptual frameworks have been developed to conceptualize and guide treatments for other types of pain, such as back pain and headaches. In this article, we integrate four prominent models—the fear avoidance model, eustress endurance model, distress endurance model, and pain resilience model—to conceptualize sexual pain in women who have experienced FGC. The resulting integrative psychological pain response model will aid in providing culturally responsive clinical management of sexual pain to women who have experienced FGC. This integrative model also provides a theoretical foundation for future research in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies
- Author
-
Hemme J. Hijma, MSc and Geert Jan Groeneveld, MD, PhD
- Subjects
Early phase drug development ,Pain models ,Proof-of-mechanism ,Proof-of-concept ,Analgesics ,Clinical Trials ,Pharmacy and materia medica ,RS1-441 - Abstract
Effective treatment for many pain disorders is still lacking, which is due to the complexity of pain in general and of the underlying pathology of many pain syndromes in particular. This results in the majority of investigational analgesic drugs failing to reach registration, either due to lack of efficacy, or due to the drug's adverse effect profile. To increase the number of analgesics that reach the patient, it is essential to carefully and rationally plan the clinical development program. By including proof-of-mechanism (PoM) and/or proof-of-concept (PoC) methods in early-phase clinical drug studies, the analgesic drug developer will be better informed regarding the key characteristics of the studied drug, which will aid in making crucial decisions during the development process. Here, we describe the top 10 currently most developed analgesic drug classes, link them mechanistically to appropriate methods to demonstrate PoM and PoC in early-phase clinical trials, and include pros and cons of each of the methods described. Lastly, we discuss how each analgesic drug class requires a tailored experimental approach for proper evaluation of PoM and PoC, and how this can contribute to an efficient and question-based approach in early-phase analgesic drug research.
- Published
- 2021
- Full Text
- View/download PDF
12. Efficacy of Essential Oils in Pain: A Systematic Review and Meta-Analysis of Preclinical Evidence
- Author
-
Damiana Scuteri, Kengo Hamamura, Tsukasa Sakurada, Chizuko Watanabe, Shinobu Sakurada, Luigi Antonio Morrone, Laura Rombolà, Paolo Tonin, Giacinto Bagetta, and Maria Tiziana Corasaniti
- Subjects
essential oils ,pain models ,inflammatory pain ,neuropathic pain ,chronic pain ,systematic review ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Background: The demand for essential oils (EOs) has been steadily growing over the years. This is mirrored by a substantial increase in research concerned with EOs also in the field of inflammatory and neuropathic pain. The purpose of this present systematic review and meta-analysis is to investigate the preclinical evidence in favor of the working hypothesis of the analgesic properties of EOs, elucidating whether there is a consistent rational basis for translation into clinical settings.Methods: A literature search has been conducted on databases relevant for medical scientific literature, i.e., PubMed/MEDLINE, Scopus, and Web of Science from database inception until November 2, 2020, following the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) criteria for systematic reviews and meta-analyses.Results: The search was conducted in order to answer the following PICOS (participants/population, interventions, comparisons, outcomes, and study design) question: are EOs efficacious in reducing acute nociceptive pain and/or neuropathic pain in mice experimental models? The search retrieved 2,491 records, leaving 954 studies to screen after the removal of duplicates. The title and abstract of all 954 studies were screened, which left 127 records to evaluate in full text. Of these, 30 articles were eligible for inclusion.Conclusion: Most studies (27) assessed the analgesic properties of EOs on acute nociceptive pain models, e.g. the acetic acid writhings test, the formalin test, and the hot plate test. Unfortunately, efficacy in neuropathic pain models, which are a more suitable model for human conditions of chronic pain, had fewer results (only three studies). Moreover, some methodologies raised concerns in terms of the risk of bias. Therefore, EOs with proven efficacy in both types of pain were corroborated by methodologically consistent studies, like the EO of bergamot, which should be studied in clinical trials to enhance the translational impact of preclinical modeling on clinical pain research.
- Published
- 2021
- Full Text
- View/download PDF
13. Modality-specific facilitation of noninjurious sharp mechanical pain by topical capsaicin.
- Author
-
Shabes, Polina, Rosenberger, Daniela C., Henrich, Florian, Greffrath, Wolfgang, Treede, Rolf-Detlef, Baumgärtner, Ulf, Magerl, Walter, and C Rosenberger, Daniela
- Subjects
- *
CAPSAICIN , *PAIN perception , *SURGICAL site , *PAIN , *HYPERALGESIA , *HEAT , *RESEARCH , *PAIN measurement , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *PAIN threshold , *COMPARATIVE studies - Abstract
We had previously shown that a "blunt blade" stimulator can mimic the noninjurious strain phase of incisional pain, but not its sustained duration. Here, we tested whether acute sensitization of the skin with topical capsaicin can add the sustained phase to this noninvasive surrogate model of intraoperative pain. Altogether, 110 healthy volunteers (55 male and 55 female; 26 ± 5 years) participated in several experiments using the "blunt blade" (0.25 × 4 mm) on normal skin (n = 36) and on skin pretreated by a high-concentration capsaicin patch (8%, Qutenza; n = 36). These data were compared with an experimental incision (n = 40) using quantitative and qualitative pain ratings by numerical rating scale and SES Pain Perception Scale descriptors. Capsaicin sensitization increased blade-induced pain magnitude and duration significantly (both P < 0.05), but it failed to fully match the sustained duration of incisional pain. In normal skin, the SES pattern of pain qualities elicited by the blade matched incision in pain magnitude and pattern of pain descriptors. In capsaicin-treated skin, the blade acquired a significant facilitation only of the perceived heat pain component (P < 0.001), but not of mechanical pain components. Thus, capsaicin morphed the descriptor pattern of the blade to become more capsaicin-like, which is probably explained best by peripheral sensitization of the TRPV1 receptor. Quantitative sensory testing in capsaicin-sensitized skin revealed hyperalgesia to heat and pressure stimuli, and loss of cold and cold pain sensitivity. These findings support our hypothesis that the blade models the early tissue-strain-related mechanical pain phase of surgical incisions. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Chronic pain impact on rodents' behavioral repertoire.
- Author
-
Cunha, Ana Margarida, Pereira-Mendes, Joana, Almeida, Armando, Guimarães, Marco Rafael, and Leite-Almeida, Hugo
- Subjects
- *
CHRONIC pain , *PAIN measurement , *EXECUTIVE function , *RODENTS , *ANXIETY - Abstract
• Rodents have a diverse behavioral repertoire. • Chronic pain impacts on multiple dimensions of rodents' behavior. • Sex, age and pain duration affect behavior under chronic pain conditions. • Mood and cognitive function can be used as proxies of pain-related disability. Rodent models have been fundamental to understand chronic pain (CP) pathophysiology and to test for potential treatments. Pain assessment in CP models is most frequently based on the evaluation of allodynia or hyperalgesia. However, these correspond only to a part of CP-related problems which include ongoing pain, depression, anxiety, disrupted sleep and attentional deficits. A growing number of preclinical studies have been assessing these manifestations in CP rodent models. We reviewed and systematized this information by behavioral domain. Observational studies in ethologically relevant conditions, paradigms of anxiety- and depressive-like behavior as well as of memory and executive function were selected. A considerable number of studies reported deficits similar to those observed in CP patients. These behavioral alterations are informative regarding ongoing maladaptive plasticity in multiple brain regions and its use as pain proxies has the potential to greatly improve the predictive value of CP models. However, the inclusion of female and/or older rodents is rare which is in clear dissonance with the clinical representation of CP. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Peripheral mechanisms of arthritic pain: A proposal to leverage large animals for in vitro studies
- Author
-
Sampurna Chakrabarti, Minji Ai, Frances M.D. Henson, and Ewan St. John Smith
- Subjects
Arthritis ,Large animals ,Sensory neurons ,In vitro ,Pain models ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Pain arising from musculoskeletal disorders such as arthritis is one of the leading causes of disability. Whereas the past 20-years has seen an increase in targeted therapies for rheumatoid arthritis (RA), other arthritis conditions, especially osteoarthritis, remain poorly treated. Although modulation of central pain pathways occurs in chronic arthritis, multiple lines of evidence indicate that peripherally driven pain is important in arthritic pain. To understand the peripheral mechanisms of arthritic pain, various in vitro and in vivo models have been developed, largely in rodents. Although rodent models provide numerous advantages for studying arthritis pathogenesis and treatment, the anatomy and biomechanics of rodent joints differ considerably to those of humans. By contrast, the anatomy and biomechanics of joints in larger animals, such as dogs, show greater similarity to human joints and thus studying them can provide novel insight for arthritis research. The purpose of this article is firstly to review models of arthritis and behavioral outcomes commonly used in large animals. Secondly, we review the existing in vitro models and assays used to study arthritic pain, primarily in rodents, and discuss the potential for adopting these strategies, as well as likely limitations, in large animals. We believe that exploring peripheral mechanisms of arthritic pain in vitro in large animals has the potential to reduce the veterinary burden of arthritis in commonly afflicted species like dogs, as well as to improve translatability of pain research into the clinic.
- Published
- 2020
- Full Text
- View/download PDF
16. Divergent response of low‐ versus high‐threshold motor units to experimental muscle pain.
- Author
-
Martinez‐Valdes, Eduardo, Negro, Francesco, Farina, Dario, and Falla, Deborah
- Subjects
- *
MOTOR unit , *MYALGIA , *EFFERENT pathways , *HYPERTONIC saline solutions , *MUSCLE fatigue , *SALINE injections , *POSTPOLIOMYELITIS syndrome - Abstract
Key points: The neural strategies behind the control of force during muscle pain are not well understood as previous research has been limited in assessing pain responses only during low‐force contractions.Here we compared, for the first time, the behaviour of motor units recruited at low and high forces in response to pain.The results showed that motor units activated at low forces were inhibited while those recruited at higher forces increased their activity in response to pain.When analysing lower‐ and higher‐threshold motor unit behaviour at high forces we observed differential changes in discharge rate and recruitment threshold across the motor unit pool.These adjustments allow the exertion of high forces in acutely painful conditions but could eventually lead to greater fatigue and stress of the muscle tissue. During low‐force contractions, motor unit discharge rates decrease when muscle pain is induced by injecting nociceptive substances into the muscle. Despite this consistent observation, it is currently unknown how the central nervous system regulates motor unit behaviour in the presence of muscle pain at high forces. For this reason, we analysed the tibialis anterior motor unit behaviour at low and high forces. Surface EMG signals were recorded from 15 healthy participants (mean age (SD) 26 (3) years, six females) using a 64‐electrode grid while performing isometric ankle dorsiflexion contractions at 20% and 70% of the maximum voluntary force (MVC). Signals were decomposed and the same motor units were tracked across painful (intramuscular hypertonic saline injection) and non‐painful (baseline, isotonic saline, post‐pain) contractions. At 20% MVC, discharge rates decreased significantly in the painful condition (baseline vs. pain: 12.7 (1.1) Hz to 11.5 (0.9) Hz, P < 0.001). Conversely, at 70% MVC, discharge rates increased significantly during pain (baseline vs. pain: 19.7 (2.8) Hz to 21.3 (3.5) Hz, p = 0.029) and recruitment thresholds decreased (baseline vs. pain: 59.0 (3.9) %MVC to 55.9 (3.2) %MVC, p = 0.02). These results show that there is a differential adjustment between low‐ and high‐threshold motor units during painful conditions. An increase in excitatory drive to high‐threshold motor units is likely required to compensate for the inhibitory influence of nociceptive afferent inputs on low‐threshold motor units. These differential mechanisms allow the force output to be maintained during acute pain but this strategy could lead to increased muscle fatigue and symptom aggravation in the long term. Key points: The neural strategies behind the control of force during muscle pain are not well understood as previous research has been limited in assessing pain responses only during low‐force contractions.Here we compared, for the first time, the behaviour of motor units recruited at low and high forces in response to pain.The results showed that motor units activated at low forces were inhibited while those recruited at higher forces increased their activity in response to pain.When analysing lower‐ and higher‐threshold motor unit behaviour at high forces we observed differential changes in discharge rate and recruitment threshold across the motor unit pool.These adjustments allow the exertion of high forces in acutely painful conditions but could eventually lead to greater fatigue and stress of the muscle tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Experimental shoulder pain models do not validly replicate the clinical experience of shoulder pain.
- Author
-
Ford, Brendon, Cohen, Milton, Halaki, Mark, Diong, Joanna, and Ginn, Karen A.
- Abstract
Background and aims: People with shoulder pain often present with abnormal shoulder muscle function. It is not known whether shoulder pain causes or is the result of muscle dysfunction. If pain leads to muscle dysfunction, therapeutic interventions that produce shoulder pain may be contraindicated. Experimentally induced nociception can be used to investigate a causal relationship between shoulder pain and muscle dysfunction. However, the validity of current experimental shoulder pain protocols has not been established. The aim of this study was to determine whether current experimental shoulder pain protocols validly replicate the clinical experience of shoulder pain with respect to pain distribution, quality and behaviour. Methods: Nine pain free participants received two injections of hypertonic saline, one into the subacromial space and one into supraspinatus, in random order, at least 1 week apart. Investigators blind to the injection site assessed pain distribution, pain response to clinical tests which provoke shoulder pain and pain quality assessed using the McGill Pain Questionnaire. Results: Following hypertonic saline injection into both the subacromial space and supraspinatus: pain was most commonly reported in the deltoid region and did not extend beyond the elbow; the most common response to clinical tests which provoke shoulder pain was a decrease in pain; and the highest rating of pain quality was in the sensory domain with very few responses in the affective domain. Conclusions: Experimental shoulder pain induced by injection of hypertonic saline into either the subacromial space or supraspinatus produced a pain distribution similar to that observed in clinical shoulder pain, but neither experimental pain protocol could reproduce the increases in pain intensity following shoulder provocation tests or the emotional distress commonly observed in people with clinical shoulder pain. Implications: Pain induced by local shoulder nociception produced by hypertonic saline injection into shoulder structures has significant limitations as a model of clinical shoulder pain. While it is perhaps unsurprising that short duration, chemically-induced experimental pain does not replicate the quality of the clinical experience of shoulder pain, the validity of experimental shoulder pain models which produce the opposite response to provocation testing to clinical shoulder pain must be questioned. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. The role of high‐conductance calcium‐activated potassium channel in headache and migraine pathophysiology
- Author
-
Mohammad Al‐Mahdi Al‐Karagholi, Cemile Ceren Hakbilen, and Messoud Ashina
- Subjects
Pharmacology ,Migraine Disorders ,Headache ,ion channels as drug targets ,General Medicine ,potassium channels ,Toxicology ,Potassium Channels, Calcium-Activated ,pain models ,Potassium ,Humans ,migraine ,pain ,Calcium ,human - Abstract
Migraine is a common, neurovascular headache disorder with a complex molecular interplay. The involvement of ion channels in the pathogenesis of migraine gathered considerable attention with the findings that different ion channels subfamilies are expressed in trigeminovascular system, the physiological substrate of migraine pain, and several ion channel openers investigated in clinical trials with diverse primary endpoints caused headache as a frequent side effect. High-conductance (big) calcium-activated potassium (BKCa) channel is expressed in the cranial arteries and the trigeminal pain pathway. Recent clinical research revealed that infusion of BKCa channel opener MaxiPost caused vasodilation, headache and migraine attack. Thus, BKCa channel is involved in pathophysiological mechanisms underlying headache and migraine, and targeting BKCa channel presents a new potential strategy for migraine treatment.
- Published
- 2022
19. Behavioral Pharmacology of Pain
- Author
-
Berge, Odd-Geir, Geyer, Mark A., Series editor, Ellenbroek, Bart A., Series editor, Marsden, Charles A., Series editor, Taylor, Bradley K., editor, and Finn, David P., editor
- Published
- 2014
- Full Text
- View/download PDF
20. Maximum tolerant dose and analgesic activity of PT1 peptide.
- Author
-
Palikova, Yuliya A., Palikov, Viktor A., and Dyachenko, Igor A.
- Subjects
NEUROTRANSMITTERS ,CHRONIC pain ,CHLORIDES ,NEURAL receptors ,AMINO acids ,CHROMATOGRAPHIC analysis - Abstract
Introduction: The article presents the results of the study of the maximum tolerant dose (MTD) and the analgesic activity of peptide PT1 isolated from Alopecosa marikovskyi spider venom. PT1 is the first compound of polypeptide nature, capable of exerting a selective modulating effect on purinergic P2X3 receptors. Materials and methods: The study was conducted on 174 ICR mice. The analgesic activity of the peptide was evaluated in a thermal hypersensitivity test triggered by CFA and in a model of chemical irritation. Results and discussion: The determined MTD for the peptide PT1 when administered intravenously provides evidence to attribute it to low-toxic compounds. The maximum analgesic activity of PT1 using the biomodel of hypersensitivity induced by CFA when tested 15 minutes after the administration was recorded at doses of 0.1 and 0.5 mg/kg. In the visceral pain test, the maximum analgesic activity 15 minutes after the administration of the chemical stimulus was observed at a dose of 0.01 mg/kg. Conclusions: According to the results of testing peptide PT1, it is shown that it belongs to low-toxic compounds, has a pronounced analgesic activity in a wide range of doses of 0.0001-10 mg/kg. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
21. Pressure Algometry for the Detection of Mechanical Nociceptive Thresholds in Horses
- Author
-
Kevin K. Haussler
- Subjects
pressure algometry ,mechanical nociceptive thresholds ,nociception ,pain ,pain models ,pain detection ,Veterinary medicine ,SF600-1100 ,Zoology ,QL1-991 - Abstract
The clinical assessment of pain is subjective; therefore, variations exist between practitioners in their ability to identify and localize pain. Due to differing interpretations of the signs or severity of pain equine practitioners may assign varying levels of clinical significance and treatment options. There is a critical need to develop better tools to qualify and quantify pain in horses. Palpation is the most common method to detect local tenderness or sensitivity. To quantify this applied pressure, pressure algometry has been used to gradually apply pressure over specified landmarks until an avoidance response is noted, which is defined as the mechanical nociceptive threshold (MNT). Numerous studies have used pressure algometry in different applications to measure MNTs in horses. There is an acute need to establish normative values within different body regions and to develop standardized methods of testing MNTs to better guide practitioners in the diagnosis and treatment of pain. The aim of this systematic review was to summarize the evidence for the use of pressure algometry in horses. There is good evidence that pressure algometry is a repeatable, semi-objective method that can be used in a wide array of clinical and research applications to assess MNTs in horses.
- Published
- 2020
- Full Text
- View/download PDF
22. Involvement of TRPM2 in a wide range of inflammatory and neuropathic pain mouse models
- Author
-
Kanako So, Kayo Haraguchi, Kayoko Asakura, Koichi Isami, Shinya Sakimoto, Hisashi Shirakawa, Yasuo Mori, Takayuki Nakagawa, and Shuji Kaneko
- Subjects
TRPM2 ,Inflammatory pain ,Neuropathic pain ,Pain models ,Knockout mice ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Recent evidence suggests a role of transient receptor potential melastatin 2 (TRPM2) in immune and inflammatory responses. We previously reported that TRPM2 deficiency attenuated inflammatory and neuropathic pain in some pain mouse models, including formalin- or carrageenan-induced inflammatory pain, and peripheral nerve injury-induced neuropathic pain models, while it had no effect on the basal mechanical and thermal nociceptive sensitivities. In this study, we further explored the involvement of TRPM2 in various pain models using TRPM2-knockout mice. There were no differences in the chemonociceptive behaviors evoked by intraplantar injection of capsaicin or hydrogen peroxide between wildtype and TRPM2-knockout mice, while acetic acid-induced writhing behavior was significantly attenuated in TRPM2-knockout mice. In the postoperative incisional pain model, no difference in mechanical allodynia was observed between the two genotypes. By contrast, mechanical allodynia in the monosodium iodoacetate-induced osteoarthritis pain model and the experimental autoimmune encephalomyelitis model were significantly attenuated in TRPM2-knockout mice. Furthermore, mechanical allodynia in paclitaxel-induced peripheral neuropathy and streptozotocin-induced painful diabetic neuropathy models were significantly attenuated in TRPM2-knockout mice. Taken together, these results suggest that TRPM2 plays roles in a wide range of pathological pain models based on peripheral and central neuroinflammation, rather than physiological nociceptive pain.
- Published
- 2015
- Full Text
- View/download PDF
23. Evaluation of anticonvulsant and analgesic activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and –butanamides.
- Author
-
Rapacz, Anna, Głuch-Lutwin, Monika, Mordyl, Barbara, Filipek, Barbara, Abram, Michał, and Kamiński, Krzysztof
- Subjects
- *
ANTICONVULSANTS , *ANALGESICS , *NEUROLOGICAL disorders , *TREATMENT of epilepsy , *DRUG resistance , *DRUG efficacy - Abstract
Epilepsy is a chronic neurological disorder that is associated with various types of recurrent seizures, which are drug-resistant in about one third of patients. Moreover, anticonvulsant drugs are used to treat a wide range of non-epileptic conditions, including chronic pain. Here, we investigated the anticonvulsant activity of six new hybrid compounds based on the pyrrolidine-2,5-dione scaffold in the 6 Hz corneal stimulation test with 44 mA stimulus intensity in mice, which is the model of pharmacoresistant seizures. We demonstrated that two molecules, DK-10 (11) and DK-14 (14) show higher anticonvulsant activity and similar safety profile in comparison with valproic acid and much higher in comparison with levetiracetam in the aforementioned test. The second aim of this study was to examine analgesic activity of these compounds. For this purpose, the hot plate test, the formalin test, and the oxaliplatin-induced peripheral neuropathy model were performed. Among tested agents DK-11 (12) revealed prominent antinociceptive activity at non-sedative doses in the second (inflammatory) phase of the formalin test, which is the model of tonic pain and antiallodynic activity in the oxaliplatin-induced neuropathic pain, the model of painful chemotherapy-induced peripheral neuropathy. No cytotoxic effect on hepatoma cells was observed. Compound DK-10 (11) had high affinity for voltage-gated sodium channels, whereas compound DK-11 (12) showed weak binding toward sodium and calcium voltage-gated channels and the NMDA receptor. As a result, hybrid compounds reported herein seem to be very promising broad spectrum anticonvulsant molecules with collateral analgesic activity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.
- Author
-
Sałat, Kinga, Furgała, Anna, and Sałat, Robert
- Subjects
- *
NOCICEPTIN , *OPIOID receptors , *CANCER pain treatment , *CANCER chemotherapy , *ALLODYNIA , *THERAPEUTICS - Abstract
Background: Cebranopadol (a.k.a. GRT-6005) is a dually acting nociceptin/orphanin FQ and opioid receptor agonist that has been recently developed in Phase 2 clinical trials for painful diabetic neuropathy or cancer pain. It also showed analgesic properties in various rat models of pain and had a better safety profile as compared to equi-analgesic doses of morphine. Since antinociceptive properties of cebranopadol have been studied mainly in rat models, in the present study, we assessed analgesic activity of subcutaneous cebranopadol (10 mg/kg) in various mouse pain models.Methods: We used models of acute, tonic, and chronic pain induced by thermal and chemical stimuli, with a particular emphasis on pharmacoresistant chronic neuropathic pain evoked by oxaliplatin in which cebranopadol was used alone or in combination with simvastatin.Key results: As shown in the hot plate test, the analgesic activity of cebranopadol developed more slowly as compared to morphine (90-120 min vs. 60 min). Cebranopadol displayed a significant antinociceptive activity in acute pain models, i.e., the hot plate, writhing, and capsaicin tests. It attenuated nocifensive responses in both phases of the formalin test and reduced cold allodynia in oxaliplatin-induced neuropathic pain model. Its efficacy was similar to that of morphine. Used in combination and administered simultaneously, 4 or 6 h after simvastatin, cebranopadol did not potentiate antiallodynic activity of this cholesterol-lowering drug. Cebranopadol did not induce any motor deficits in the rotarod test.Conclusion: Cebranopadol may have significant potential for the treatment of various pain types, including inflammatory and chemotherapy-induced neuropathic pain. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain.
- Author
-
Sałat, Kinga, Kołaczkowski, Marcin, Furgała, Anna, Rojek, Adriana, Śniecikowska, Joanna, Varney, Mark A., and Newman-Tancredi, Adrian
- Subjects
- *
DYSKINESIAS , *ANALGESICS , *ALLODYNIA , *HYPERALGESIA , *DIABETIC neuropathies , *DIAGNOSIS , *THERAPEUTICS - Abstract
Background and purpose: NLX-112 (a.k.a. befiradol, F13640) is a drug candidate intended for the treatment of l -DOPA-induced dyskinesia. It is a highly selective serotonin 5-HT 1A receptor full agonist which has been previously tested in a variety of models of CNS effects including analgesic activity in rat. Its activity in mouse models of pain has not been previously investigated. Experimental approach The activity of NLX-112 was tested in mouse models of acute pain (hot plate), tonic pain (intraplantar formalin test), in the oxaliplatin-induced neuropathic pain model of chemotherapy-induced peripheral neuropathy and in the streptozotocin (STZ)-induced model of painful diabetic neuropathy. Key results The main findings indicate that (i) NLX-112 was markedly active in the formalin test with potent reduction of paw licking in both phases of the test (minimal effective dose (MED) 0.5 mg/kg i.p. and p.o. in acute phase, and 0.1 mg/kg i.p. and 1 mg/kg p.o. in late phase). The effects of NLX-112 in this test were completely abolished by the selective 5-HT 1A receptor antagonist, WAY100635; (ii) NLX-112 was active in the hot plate test and in the oxaliplatin-induced neuropathic pain model of chemotherapy-induced peripheral neuropathy, but at markedly higher doses (MED 2.5 mg/kg i.p.); (iii) NLX-112 was least active in the STZ-induced model of painful diabetic neuropathy (MED 5 mg/kg i.p.); (iv) NLX-112 did not affect locomotor activity. Conclusions and implications NLX-112 may have significant potential for treatment of tonic pain but may be less promising as a candidate for treatment of chemotherapy-induced or diabetic neuropathic pain. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
26. Interactions with pain-related systems - Towards new electrical treatments for chronic pain
- Author
-
Forni, Matilde
- Subjects
Physiology ,Medical Biotechnology ,Periaqueductal gray matter ,Neurosciences ,High definition brain stimulation ,Pain models ,Pain systems - Abstract
Background. Persistent intolerable pain is still an unsolved issue with a huge socioeconomic impact. To develop appropriate treatments, it is crucial to understand the complex mechanisms underlying pain and how they change during sustained pain stimuli or during pathological conditions. In particular, it is essential to clarify how the endogenous analgesic centres which are present in the brain, such as periaqueductal grey (PAG) matter and dorsal raphe nuclei (DRN) in the brainstem, modulate pain by interfering with the nociceptive information. Deep brain stimulation of these areas can elicit potent analgesia. However, it has not been possible to exploit its full analgesic potential due to the insufficient stimulation specificity of the state-of-the-art probes.Aim. To address this challenge, we developed and implanted in rodents, a novel probe for high-definition brain stimulation (HDBS) based on the spread in 3D of ultra-flexible microelectrodes in PAG/DRN. The probe comprised 16 ultra-flexible microelectrodes embedded in a gelatine needle-like probe. The main aim was to elucidate whether stimulation of individually selected microelectrodes can selectively activate the anti-nociceptive pathways without activating networks that provoke side effects.Methodology. The selection of an appropriate microelectrode subset and stimulation intensity was done by monitoring the withdrawal reflexes elicited by CO2 laser stimuli and by simultaneous behavioural observations in awake freely moving animals. To evaluate the effect of HDBS in PAG/DRN on the nociceptive pathways related to pain perception, microelectrode recordings were made in cortical areas known to be involved in the sensory-discriminative and affective aspects of pain. Clinically relevant aspects such as potency, specificity, sustainability, reliability of HDBS as well as efficacy in conditions with hypersensitivity to nociceptive stimuli (hyperalgesia) were assessed by recording nociceptive-evoked cortical responses, withdrawal reflexes, gait and normal behaviours. To assess the presence of side effects, HDBS effect on intracortical spontaneous activity, brain states (ECoGs), behaviour in an open field, and the tactile input to cortex was also investigated. The tissue reactions to the implanted stimulation probe and the probe placement were evaluated using immunohistochemistry. In addition, we investigated whether tissue reactions related to probe implantation can be mitigated by incorporating PLGA-nanoparticles loaded with an anti-inflammatory drug, minocycline, and embedded into a gelatine vehicle.Results. For all the animals with verified placement within or nearby PAG/DRN, it was possible to individually select a microelectrode subset and stimulation intensity, which strongly inhibit nociceptive-evoked withdrawal reflexes without noticeable side effects. The selected microelectrode combinations also reduced nociceptive-evoked cortical responses (related to both discriminative and affective pain) in normal conditions and during hyperalgesia. The HDBS-induced analgesia could be sustained for at least 4 hours and did not provoke significant side effects on behaviour, spontaneous activity, and brain states and it had a minor effect on the tactile afferent pathway to the cortex. Histological analysis showed minimal tissue reactions and neuronal death around the stimulation implant. Minocycline containing PLGA nanoparticles significantly reduced glial reactions without signs of toxicity. Conclusions. These results show that granular and high-resolution PAG/DRN stimulation enables potent, specific, safe, and durable analgesia by blocking the nociceptive-evoked motor, sensory and affective responses without significant activation of pathways provoking adverse side effects. Therefore, HDBS in PAG/DRN holds great promise as an efficient treatment of intractable chronic pain disorders.
- Published
- 2022
27. Papain as a Potential New Experimental Model of Non-histaminergic Itch
- Author
-
Giulia Erica Aliotta, Zeinab Saii, Jesper Elberling, Lars Arendt-Nielsen, and Silvia Lo Vecchio
- Subjects
Pruritus ,ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS ,Pain Models ,non-histaminergic itch ,Dermatology ,General Medicine ,Models, Theoretical ,ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS ,papain ,Basic Science ,Papain ,Pruritus/drug therapy ,Humans ,ComputingMethodologies_GENERAL ,itch ,InformationSystems_MISCELLANEOUS ,Skin - Abstract
is missing (Short communication)
- Published
- 2022
28. Preclinical Comparison of Mechanistically Different Antiseizure, Antinociceptive, and/or Antidepressant Drugs in a Battery of Rodent Models of Nociceptive and Neuropathic Pain.
- Author
-
Smith, Misty, Woodhead, Jose, Handy, Laura, Pruess, Timothy, Vanegas, Fabiola, Grussendorf, Erin, Grussendorf, Joel, White, Karen, Bulaj, Karolina, Krumin, Reisa, Hunt, Megan, and Wilcox, Karen
- Subjects
- *
ANTICONVULSANTS , *EPILEPSY , *BRAIN diseases , *DRUG development , *SEIZURES (Medicine) , *PLACEBOS - Abstract
The series of experiments herein evaluated prototype drugs representing different mechanisms of antiseizure, antinociceptive or antidepressant action in a battery of preclinical pain models in adult male CF#1 mice (formalin, writhing, and tail flick) and Sprague Dawley rats partial sciatic nerve ligation (PSNL). In the formalin assay, phenytoin (PHT, 6 mg/kg), sodium valproate (VPA, 300 mg/kg), amitriptyline (AMI, 7.5 and 15 mg/kg), gabapentin (GBP, 30 and 70 mg/kg), tiagabine (TGB, 5 and 15 mg/kg), and acetominophen (APAP, 250 and 500 mg/kg) reduced both phases of the formalin response to ≤ 25% of vehicle-treated mice. In the acetic acid induced writhing assay, VPA (300 mg/kg), ethosuximide (ETX, 300 mg/kg), morphine (MOR, 5 & 10 mg/kg), GBP (10, 30, and 60 mg/kg), TGB (15 mg/kg), levetiracetam (LEV, 300 mg/kg), felbamate (FBM, 80 mg/kg) and APAP (250 mg/kg) reduced writhing to ≤ 25% of vehicle-treated mice. In the tail flick test, MOR (1.25-5 mg/kg), AMI (15 mg/kg) and TGB (5 mg/kg) demonstrated significant antinociceptive effects. Finally, carbamazepine (CBZ, 20 and 50 mg/kg), VPA, MOR (2 and 4 mg/kg), AMI (12 mg/kg), TPM (100 mg/kg), lamotrigine (LTG, 40 mg/kg), GBP (60 mg/kg), TGB (15 mg/kg), FBM (35 mg/kg), and APAP (250 mg/kg) were effective in the PSNL model. Thus, TGB was the only prototype compound with significant analgesic effects in each of the four models, while AMI, GBP, APAP, and MOR each improved three of the four pain phenotypes. This study highlights the importance evaluating novel targets in a variety of pain phenotypes. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. Midazolam as an active placebo in 3 fentanyl-validated nociceptive pain models.
- Author
-
Prosenz, Julian and Gustorff, Burkhard
- Subjects
- *
MIDAZOLAM , *PLACEBOS , *NOCICEPTIVE pain , *FENTANYL , *CLINICAL trials , *ANALGESICS , *COMPARATIVE studies , *CROSSOVER trials , *RESEARCH methodology , *MEDICAL cooperation , *PAIN , *SENSORY perception , *RESEARCH , *EVALUATION research , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *HUMAN research subjects , *BLIND experiment , *PAIN threshold , *PHARMACODYNAMICS , *THERAPEUTICS - Abstract
The use of inactive placebos in early translational trials of potentially analgesic compounds is discouraged because of the side-effect profiles of centrally acting analgesics. Therefore, benzodiazepines are used, although their use has not been validated in this context. Whether benzodiazepines confound the results of acute pain tests is unknown. Midazolam (0.06 mg/kg) as an active placebo was investigated in 3 nociceptive models that included contact heat, electrical pain, and pressure pain thresholds in 24 healthy volunteers. Fentanyl (1 μg/kg) served as an internal validator in this randomized, placebo (saline) controlled, 3-way cross-over trial. The primary outcome parameter (contact heat pain) was analyzed using a one-way, repeated measures analysis of variance and Tukey's post test. Midazolam did not reduce pain ([numeric rating scale], 0-100) in a statistically significant manner compared with placebo for the contact heat (mean difference -1.7, 95% confidence interval -10.6 to 7.3; P = 0.89) or electrical pain (4.3, -5.1 to 13.7; P = 0.51) test, nor did it raise the pressure pain thresholds (-28 kPa, -122; 64 kPa, P = 0.73). The width of the confidence intervals suggested that there were no clinically meaningful analgesic effects compared with the placebo. In contrast, the analgesic efficacy of fentanyl was effectively demonstrated in all 3 models (P < 0.01 vs midazolam and placebo). The findings of this study show that midazolam can be used as an active placebo in analgesic drug trials. Furthermore, the proposed models were simple to implement and very effective in detecting analgesia. The test battery can be used in translational trials for new compounds and comes with an active placebo and an optional active comparator. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. The spider toxin Phα1β recombinant possesses strong analgesic activity.
- Author
-
Rigo, Flavia Karine, Trevisan, Gabriela, De Prá, Samira Dal-Toé, Cordeiro, Marta Nascimento, Borges, Marcia Helena, Silva, Juliana Figueiredo, Santa Cecilia, Flavia Viana, de Souza, Alessandra Hubner, de Oliveira Adamante, Gabriela, Milioli, Alessandra Marcon, de Castro Junior, Célio José, Ferreira, Juliano, and Gomez, Marcus Vinicius
- Subjects
- *
SPIDER venom , *PAIN management , *ANALGESICS , *RECOMBINANT proteins , *VOLTAGE-gated ion channels - Abstract
The native Phα1β – a Voltage-Gated Calcium Channel (VGCC) blocker – and its Recombinant Version – were both tested in rodent pain models with an intraplantar injections of capsaicin or formalin, a chronic constriction injury, and melanoma cancer related pain. The formalin nociceptive behaviour in the neurogenic phase was not affected by the toxin pre-treatments, while in the inflammatory phase, Phα1β and the Recombinant form caused a significant reduction. The nociception that was triggered by capsaicin, an agonist of the TRPV1 vanilloid receptor, was totally blocked by 100 pmol/site, i.t. of Phα1β or the recombinant version. For the neuropathic pain that was induced by a chronic constriction injury of the sciatic nerve, Phα1β and its Recombinant reduced the allodynia that was induced by the CCI procedure in the rats and the hypersensitivity lasted for 4 h. Fourteen days after the inoculation of the B16-F10 melanoma cells in the mice, a marked hyperalgesia was induced in the melanoma cancer pain model. Phα1β and the Recombinant form reduced the hyperalgesia with a full reversion at 100 pmol/site i.t. The inhibitory effects of the nociception that was induced by native Phα1β and the Recombinant in the studied pain models were not statistically different and they developed with no side effects. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. Human experimental pain models: A review of standardized methods in drug development
- Author
-
K. Sunil kumar Reddy, M. U. R Naidu, Usha P Rani, and T. Ramesh Kumar Rao
- Subjects
Analgesics ,multimodel-multitissue ,pain models ,proof-of-concept ,spontaneous pain ,Medicine - Abstract
Human experimental pain models are essential in understanding the pain mechanisms and appear to be ideally suited to test analgesic compounds. The challenge that confronts both the clinician and the scientist is to match specific treatments to different pain-generating mechanisms and hence reach a pain treatment tailored to each individual patient. Experimental pain models offer the possibility to explore the pain system under controlled settings. Standardized stimuli of different modalities (i.e., mechanical, thermal, electrical, or chemical) can be applied to the skin, muscles, and viscera for a differentiated and comprehensive assessment of various pain pathways and mechanisms. Using a multimodel-multistructure testing, the nociception arising from different body structures can be explored and modulation of specific biomarkers by new and existing analgesic drugs can be profiled. The value of human experimental pain models is to link animal and clinical pain studies, providing new possibilities for designing successful clinical trials. Spontaneous pain, the main compliant of the neuropathic patients, but currently there is no human model available that would mimic chronic pain. Therefore, current human pain models cannot replace patient studies for studying efficacy of analgesic compounds, although being helpful for proof-of-concept studies and dose finding.
- Published
- 2012
32. A novel human surrogate model of noninjurious sharp mechanical pain.
- Author
-
Shabes, Polina, Schloss, Natalie, Magerl, Walter, Schmahl, Christian, Treede, Rolf-Detlef, and Baumgärtner, Ulf
- Subjects
- *
PAIN , *SELF-injurious behavior , *BORDERLINE personality disorder , *POSTOPERATIVE pain , *QUESTIONNAIRES , *HYPERALGESIA , *PAIN measurement , *PAIN threshold - Abstract
We propose a blade as a noninjurious nociceptive stimulus modeling sharp mechanical pain and yielding acute pain and hyperalgesia responses with closer proximity to incision-induced pain/hyperalgesia than punctate or blunt pressure mechanical pain models. Twenty-six healthy men and women were investigated to compare a small incision in the left forearm with noninvasive stimuli of different shapes and modalities to the right forearm. The magnitude and time course of incisional and blade-induced pain were assessed by numerical rating scales. Affective vs sensory components of pain experience were differentiated using a pain sensation questionnaire. The magnitude and time course of the axon reflex vasodilator response and of secondary hyperalgesia following a 7-second blade application were assessed. The maximum blade or incisional pain was similar (visual analogue scale [mean ± SD]: 32.9 ± 22.5 [blade] vs. 33.6 ± 29.8 [incision]), and both time courses matched closely in the first 10 seconds (paired t test; P = 0.5-1.0), whereas incision but not blade was followed by a second phase of pain, probably related to the tissue injury (decrease to half maximum pain 8 ± 2 vs. 33 ± 35 seconds; P < 0.01). Affective pain scores were significantly lower than sensory scores for all stimuli (P < 0.001). Comparing blade and incision, patterns of affective and sensory pain descriptors exhibited a remarkably similar pattern. Hence, we suggest the blade as novel model of sharp mechanical pain, which will be useful in investigating postoperative/mechanical pain and the role of self-injurious behavior in, eg, patients with borderline personality disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. The roles of ethnicity, sex, and parental pain modeling in rating of experienced and imagined pain events.
- Author
-
Boissoneault, Jeff, Bunch, Jennifer, and Robinson, Michael
- Subjects
- *
ANALYSIS of variance , *CHI-squared test , *CONFIDENCE intervals , *LEARNING , *PARENTING , *RACE , *RESEARCH funding , *SEX distribution , *PAIN measurement , *UNDERGRADUATES , *DATA analysis software , *DESCRIPTIVE statistics , *ODDS ratio , *PAIN threshold - Abstract
To investigate the association of ethnicity, sex, and parental pain modeling on the evaluation of experienced and imagined painful events, 173 healthy volunteers (96 women) completed the Prior Pain Experience Questionnaire, a 79-question assessment of the intensity of painful events, and a questionnaire regarding exposure to parental pain models. Consistent with existing literature, greater ratings of experienced pain were noted among Black versus White participants. Parental pain modeling was associated with higher imagined pain ratings, but only when the parent matched the participant's sex. This effect was greater among White and Asian participants than Black or Hispanic participants, implying ethno-cultural effects may moderate the influence of pain modeling on the evaluation of imagined pain events. The clinical implications of these findings, as well as the predictive ability of imagined pain ratings for determining future experiences of pain, should be investigated in future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. Electrophysiological Changes in Motor Preparation During Muscle Pain Induced by Short Wave Diathermy:Preliminary Results
- Author
-
Mista, Christian, Laugero, S., Adur, J., Andersen, Ole Kæseler, and Biurrun Manresa, José
- Subjects
ComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMS ,Basic Science ,ComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKS ,Pain Models ,InformationSystems_MISCELLANEOUS - Abstract
Poster ID: 1041439 Abstract ID: 1041439
- Published
- 2021
35. Efficacy of ketamine in relieving neuropathic pain: a systematic review and meta-analysis of animal studies
- Author
-
Jeffrey S. Mogil, Albert Dahan, Carlijn R. Hooijmans, Monique van Velzen, Jack D.C. Dahan, and Eveline L. A. van Dorp
- Subjects
Chronic pain ,Neuropathic pain ,Pain models ,Mice ,Animal data ,Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2] ,medicine ,Animals ,Ketamine ,Dosing ,business.industry ,Rats ,Animal models ,Anesthesiology and Pain Medicine ,Allodynia ,Neurology ,Hyperalgesia ,Strictly standardized mean difference ,Meta-analysis ,Anesthesia ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,Neuralgia ,Neurology (clinical) ,Animal studies ,medicine.symptom ,business ,Systematic Review and Meta-Analysis ,medicine.drug - Abstract
Supplemental Digital Content is Available in the Text., In humans, proof of long-term efficacy of ketamine treatment in neuropathic pain is lacking. To improve our understanding of ketamine behavior under various administration conditions, we performed a systematic review and meta-analyses of controlled studies on the efficacy of ketamine in mice and rats with a disease model of nerve injury on relief of allodynia. Searches in PubMed and EMBASE identified 31 unique studies. Four meta-analyses were conducted. The first analysis included 19 comparisons on a single ketamine dose and measurement of effect within 3 hours of dosing and showed an appreciable effect (standardized mean difference 1.6, 95% confidence interval 1.1-2.1). Subgroup analyses showed no effect of species, administration route, or dose. A single administration was insufficient to sustain relief of allodynia at 24 or 72 hours after dosing, as observed in our second analysis (7 comparisons) with similar effects in ketamine-treated and control animals. Chronic ketamine administration (9 comparisons) caused profound relief of allodynia when tested during ketamine exposure (effect size 5.1, 3.7-6.5). The final analysis (6 comparisons) showed that chronic administration caused a slow loss of relief of allodynia with 70% loss of effect 24 days after end of treatment. No subgroups analyses were possible in the last 3 meta-analyses due to small group sizes. These results indicate long-term ketamine anti-allodynic effects after chronic exposure (>3 days) but not after a single administration. Given several limitations, extrapolation of the animal data to the human condition is tenuous.
- Published
- 2021
36. Neuronal changes induced by Varicella Zoster Virus in a rat model of postherpetic neuralgia.
- Author
-
Guedon, Jean-Marc G., Yee, Michael B., Zhang, Mingdi, Harvey, Stephen A.K., Goins, William F., and Kinchington, Paul R.
- Subjects
- *
VARICELLA-zoster virus diseases , *HERPES zoster , *HERPES zoster diagnosis , *POSTHERPETIC neuralgia , *REVERSE transcriptase polymerase chain reaction , *LABORATORY rats , *PATIENTS - Abstract
A significant fraction of patients with herpes zoster, caused by Varicella Zoster Virus (VZV), experience chronic pain termed postherpetic neuralgia (PHN). VZV-inoculated rats develop prolonged nocifensive behaviors and serve as a model of PHN. We demonstrate that primary rat cultures show a post-entry block for VZV replication, suggesting the rat is not fully permissive. However, footpads of VZV infected animals show reduced peripheral innervation and innervating dorsal root ganglia (DRG) contained VZV DNA and transcripts of candidate immediate early and early genes. The VZV-infected DRG showed changes in host gene expression patterns, with 84 up-regulated and 116 down-regulated genes seen in gene array studies. qRT-PCR validated the modulation of nociception-associated genes Ntrk2, Trpv1, and Calca (CGRP). The data suggests that VZV inoculation of the rat results in a single round, incomplete infection that is sufficient to induce pain behaviors, and this involves infection of and changes induced in neuronal populations. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
37. Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain
- Author
-
Anna Furgała, Kinga Sałat, and Robert Sałat
- Subjects
0301 basic medicine ,Male ,Simvastatin ,Indoles ,Immunology ,Analgesic ,Cebranopadol ,Pain models ,cebranopadol ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Neurogenic inflammation ,simvastatin ,Medicine ,Animals ,Pharmacology (medical) ,Spiro Compounds ,Hot plate test ,Pain Measurement ,Pharmacology ,Chemotherapy-induced peripheral neuropathy ,Analgesics ,neurogenic inflammation ,Morphine ,business.industry ,oxaliplatin ,Chronic pain ,medicine.disease ,Oxaliplatin ,Analgesics, Opioid ,Nociceptin receptor ,Disease Models, Animal ,030104 developmental biology ,Allodynia ,Opioid Peptides ,Anesthesia ,pain models ,Neuropathic pain ,Receptors, Opioid ,Neuralgia ,Original Article ,medicine.symptom ,Chronic Pain ,business ,Cancer pain ,030217 neurology & neurosurgery ,chemotherapy-induced peripheral neuropathy - Abstract
Background Cebranopadol (a.k.a. GRT-6005) is a dually acting nociceptin/orphanin FQ and opioid receptor agonist that has been recently developed in Phase 2 clinical trials for painful diabetic neuropathy or cancer pain. It also showed analgesic properties in various rat models of pain and had a better safety profile as compared to equi-analgesic doses of morphine. Since antinociceptive properties of cebranopadol have been studied mainly in rat models, in the present study, we assessed analgesic activity of subcutaneous cebranopadol (10 mg/kg) in various mouse pain models. Methods We used models of acute, tonic, and chronic pain induced by thermal and chemical stimuli, with a particular emphasis on pharmacoresistant chronic neuropathic pain evoked by oxaliplatin in which cebranopadol was used alone or in combination with simvastatin. Key results As shown in the hot plate test, the analgesic activity of cebranopadol developed more slowly as compared to morphine (90–120 min vs. 60 min). Cebranopadol displayed a significant antinociceptive activity in acute pain models, i.e., the hot plate, writhing, and capsaicin tests. It attenuated nocifensive responses in both phases of the formalin test and reduced cold allodynia in oxaliplatin-induced neuropathic pain model. Its efficacy was similar to that of morphine. Used in combination and administered simultaneously, 4 or 6 h after simvastatin, cebranopadol did not potentiate antiallodynic activity of this cholesterol-lowering drug. Cebranopadol did not induce any motor deficits in the rotarod test. Conclusion Cebranopadol may have significant potential for the treatment of various pain types, including inflammatory and chemotherapy-induced neuropathic pain.
- Published
- 2017
38. Hyperalgesia-Type Response Reveals No Difference in Pain-Related Behavior Between Wistar and Sprague-Dawley Rats
- Author
-
Katarina Vukojević, Sanja Lovrić-Kojundžić, and Damir Sapunar
- Subjects
neuropathic pain ,rat strain ,strain diff erences ,pain models ,hyperalgesia ,pain behavior ,Biology (General) ,QH301-705.5 - Abstract
The experience of pain is variable among certain cultures, ethnical groups and among individuals. This variability can be explained by environmental influence, genetic predisposition and plasticity of the existing neuronal pathways. The purpose of this study was to examine a strain-related difference in pain sensitivity between Wistar and Sprague-Dawley rats strains and if there was a difference, could it be overcomes with the robust test. Mechanical sensitivity e.g. existence of paw withdrawal and complex hyperalgesia-type response after needle stimuli has been measured. Both hindpaws (middle, medial and lateral part) were stimulated randomly in appropriate intervals. The results did not demonstrate statistically significant strain difference in pain sensitivity, except in the lateral part of the hindpaw where Sprague-Dawley rats were more sensitive. This data emphasize the importance of selecting a robust behavior test that will be used in investigation of peripheral nerve injury and in neuropathic pain research.
- Published
- 2007
- Full Text
- View/download PDF
39. Low-Dose Sublingual Ketamine Does Not Modulate Experimentally Induced Mechanical Hyperalgesia in Healthy Subjects.
- Author
-
Slater, Helen, Graven-Nielsen, Thomas, Wright, Anthony, and Schug, Stephan A.
- Subjects
- *
MUSCLE physiology , *MYALGIA , *HYPERALGESIA , *KETAMINE , *MEDICAL care , *PAIN , *PATIENTS , *STATISTICS , *DATA analysis , *DATA analysis software , *SUBLINGUAL drug administration , *DIAGNOSIS - Abstract
Objective. Musculoskeletal pain has been associated with N-methyl- d-aspartate (NMDA) receptor-mediated mechanisms. This randomized controlled trial (RCT) investigated the effect of the NMDA receptor antagonist ketamine (25 mg sublingually) on modulating experimental muscle pain. Design. Two groups (N = 11/group) of age- and sex-matched healthy subjects performed eccentric exercise using the nondominant arm wrist extensors (time 0) to induce muscle soreness 24 hours later (time 1). Intervention. Immediately prior to exercise, subjects were administered either a 25 mg ketamine lozenge or a placebo. At time 1, experimental muscle pain was augmented by injection of hypertonic saline into the extensor carpi radialis brevis (ECRB) muscle of the exercised arm. Outcome Measures. Pressure pain thresholds (PPTs), muscle soreness, muscle pain intensity (electronic visual analog scale [VAS]), and maximal wrist extension force were assessed at time 0 (pre- and postexercise) and at time 1 (pre-, during, and post saline-induced pain). Results. Regardless of group, PPT was reduced at ECRB ( P < 0.021) and at the common extensor origin ( P < 0.034) at time 1 preinjection compared with time 0 pre-exercise. At time 1, elevated levels of muscle soreness and force attenuation were similar between groups compared with time 0 pre-exercise ( P < 0.0001), and similar hypertonic saline-induced pain areas and pain intensity profiles were evident. Conclusion. In comparison with placebo, a single low-dose sublingual pharmacological intervention targeting the processes of sensitization via antagonism of NMDA receptors did not modulate the effects of acute experimentally induced mechanical hyperalgesia, suggesting a higher dose or repeat doses may be required. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
40. Human experimental pain models: A review of standardized methods in drug development.
- Author
-
Reddy, K. Sunil kumar, Naidu, M. U. R., Rani, P. Usha, and Rao, T. Ramesh Kumar
- Subjects
- *
ANALGESICS , *DECISION making , *ELECTRIC stimulation , *PAIN , *DRUG development , *PAIN measurement - Abstract
Human experimental pain models are essential in understanding the pain mechanisms and appear to be ideally suited to test analgesic compounds. The challenge that confronts both the clinician and the scientist is to match specific treatments to different pain-generating mechanisms and hence reach a pain treatment tailored to each individual patient. Experimental pain models offer the possibility to explore the pain system under controlled settings. Standardized stimuli of different modalities (i.e., mechanical, thermal, electrical, or chemical) can be applied to the skin, muscles, and viscera for a differentiated and comprehensive assessment of various pain pathways and mechanisms. Using a multimodel-multistructure testing, the nociception arising from different body structures can be explored and modulation of specific biomarkers by new and existing analgesic drugs can be profiled. The value of human experimental pain models is to link animal and clinical pain studies, providing new possibilities for designing successful clinical trials. Spontaneous pain, the main compliant of the neuropathic patients, but currently there is no human model available that would mimic chronic pain. Therefore, current human pain models cannot replace patient studies for studying efficacy of analgesic compounds, although being helpful for proof-of-concept studies and dose finding. [ABSTRACT FROM AUTHOR]
- Published
- 2012
41. Pain tests provoke modality-specific cardiovascular responses in awake, unrestrained rats
- Author
-
Rigaud, Marcel, Gemes, Geza, Abram, Stephen E., Dean, Caron, Hopp, Francis A., Stucky, Cheryl L., Eastwood, Daniel, Tarima, Sergey, Seagard, Jeanne, and Hogan, Quinn H.
- Subjects
- *
PAIN in animals , *LABORATORY rats , *HEART beat , *BIOTELEMETRY , *NEUROPATHY , *RADIANT heating , *HYPERALGESIA , *BODY temperature regulation , *SENSES , *ELECTRIC stimulation - Abstract
Abstract: Nociception modulates heart rate (HR) and mean arterial pressure (MAP), suggesting their use of HR and MAP as indicators of pain in animals. We explored this with telemetric recording in unrestrained control and neuropathic (spinal nerve ligation) rats. Plantar stimulation was performed emulating techniques commonly used to measure pain, specifically brush stroke, von Frey fiber application, noxious pin stimulation, acetone for cooling, and radiant heating, while recording MAP, HR, and specific evoked somatomotor behaviors (none; simple withdrawal; or sustained lifting, shaking, and grooming representing hyperalgesia). Pin produced elevations in both HR and MAP, and greater responses accompanied hyperalgesia behavior compared to simple withdrawal. Von Frey stimulation depressed MAP, and increased HR only when stimulation produced hyperalgesia behavior, suggesting that minimal nociception occurs without this behavior. Brush increased MAP even when no movement was evoked. Cold elevated both HR and MAP whether or not there was withdrawal, but MAP increased more when withdrawal was triggered. Heating, consistently depressed HR and MAP, independent of behavior. Other than a greater HR response to pin in animals made hyperalgesic by injury, cardiovascular events evoked by stimulation did not differ between control and neuropathic animals. We conclude that (a) thermoregulation rather than pain may dominate responses to heat and cooling stimuli; (b) brush and cooling stimuli may be perceived and produce cardiovascular activation without nocifensive withdrawal; (c) sensations that produce hyperalgesia behavior are accompanied by greater cardiovascular activation than those producing simple withdrawal; and (d) von Frey stimulation lacks cardiovascular evidence of nociception except when hyperalgesia behavior is evoked. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
42. Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies
- Author
-
Geert Jan Groeneveld and Hemme J. Hijma
- Subjects
Drug ,medicine.medical_specialty ,media_common.quotation_subject ,Analgesic ,Pain models ,Pharmacy and materia medica ,Drug Discovery ,Medicine ,Clinical Trials ,Pharmacology (medical) ,Intensive care medicine ,Adverse effect ,media_common ,Pharmacology ,Analgesics ,business.industry ,Mechanism (biology) ,Proof-of-mechanism ,RS1-441 ,Clinical trial ,Drug class ,Proof-of-concept ,Drug development ,Early phase drug development ,Proof of concept ,business - Abstract
Effective treatment for many pain disorders is still lacking, which is due to the complexity of pain in general and of the underlying pathology of many pain syndromes in particular. This results in the majority of investigational analgesic drugs failing to reach registration, either due to lack of efficacy, or due to the drug's adverse effect profile. To increase the number of analgesics that reach the patient, it is essential to carefully and rationally plan the clinical development program. By including proof-of-mechanism (PoM) and/or proof-of-concept (PoC) methods in early-phase clinical drug studies, the analgesic drug developer will be better informed regarding the key characteristics of the studied drug, which will aid in making crucial decisions during the development process. Here, we describe the top 10 currently most developed analgesic drug classes, link them mechanistically to appropriate methods to demonstrate PoM and PoC in early-phase clinical trials, and include pros and cons of each of the methods described. Lastly, we discuss how each analgesic drug class requires a tailored experimental approach for proper evaluation of PoM and PoC, and how this can contribute to an efficient and question-based approach in early-phase analgesic drug research.
- Published
- 2021
43. Experimental and Clinical Applications of Quantitative Sensory Testing Applied to Skin, Muscles and Viscera.
- Author
-
Arendt-Nielsen, Lars and Yarnitsky, David
- Abstract
Abstract: Quantification of the human painful sensory experience is an essential step in the translation of knowledge from animal nociception to human pain. Translational models for assessment of pain are very important, as such models can be used in: 1) basic mechanistic studies in healthy volunteers; 2) clinical studies for diagnostic and monitoring purposes; 3) pharmacological studies to evaluate analgesic efficacy of new and existing compounds. Quantitative pain assessment, or quantitative sensory testing (QST), provides psychophysical methods that systematically document alterations and reorganization in nervous system function and, in particular, the nociceptive system. QST is defined as the determination of thresholds or stimulus response curves for sensory processing under normal and pathophysiological conditions. The modern concept of advanced QST for experimental pain assessment is a multimodality, multitissue approach where different pain modalities (thermal, mechanical, electrical, and chemical) are applied to different tissues (skin, muscles, and viscera) and the responses are assessed by psychophysical methods (thresholds and stimulus-response functions). Many new and advanced technologies have been developed to help relieve evoked, standardized, and painful reactions. Assessing pain has become a question of solving a multi-input, multi-output problem, with the solution providing the possibility of teasing out which pain pathways and mechanisms are involved, impaired, or affected. Perspective: Many methodologies have been developed for quantitative assessment of pain perception and involved mechanisms. This paper describes the background for the different methods, the use in basic pain experiments on healthy volunteers, how they can be applied in drug profiling, and the applications in clinical practice. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
44. Targeted delivery of pharmacological agents into rat dorsal root ganglion
- Author
-
Puljak, Livia, Kojundzic, Sanja Lovric, Hogan, Quinn H., and Sapunar, Damir
- Subjects
- *
TARGETED drug delivery , *SPINAL ganglia , *PHARMACOLOGY , *LABORATORY rats , *INJECTIONS , *NEUROSCIENCES - Abstract
Abstract: We sought an optimal method for targeted delivery into dorsal root ganglia (DRGs) for experimental studies, in terms of precision of delivery and avoidance of behavioral disturbances. We examined three approaches for injection into rat DRGs: percutaneous injection without surgical exposure, injection after deep exposure, and injection following deep exposure and partial laminectomy. Coomassie blue and Fast Blue were injected into DRGs for validation. At necropsy, the spread of Coomassie blue and Fast Blue was investigated under stereomicroscope and fluorescent microscope, respectively. We found that percutaneous approach did not provide any successful DRG injections. Deep exposure prior to intraganglionic injection provided variable results, but intraganglionic injection after deep exposure plus partial laminectomy was successful in 100% of attempts. Our subsequent skeletal analysis showed that the anatomical location of DRG is not compatible with successful DRG injection without surgical exposure. Neither of the methods using surgical exposure caused behavioral disturbances. Based on these results we conclude that partial laminectomy offers the most precise method of injecting DRG and does not produce behavioral evidence of nerve damage. Intraganglionic injection after deep exposure alone is less predictable, while percutaneous approaches only allow injection in the peripheral nerve. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
45. Weder Descartes noch Freud? Aktuelle Schmerzmodelle in der Psychosomatik.
- Author
-
Egloff, N., von Känel, R., and Egle, U.T.
- Abstract
Models explaining chronic pain based on the mere presence or absence of peripheral somatic findings or which view pain of psychological origin when there is no somatic explanation, have their shortcomings. Current scientific knowledge calls for distinct pain concepts, which integrate neurobiological and neuropsychological aspects of pain processing. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
46. Species and strain differences in rodent sciatic nerve anatomy: Implications for studies of neuropathic pain
- Author
-
Rigaud, Marcel, Gemes, Geza, Barabas, Marie-Elizabeth, Chernoff, Donna I., Abram, Stephen E., Stucky, Cheryl L., and Hogan, Quinn H.
- Subjects
- *
HINDLIMB , *PAIN , *RATS , *SCIATIC nerve - Abstract
Abstract: Hindlimb pain models developed in rats have been transposed to mice, but assumed sciatic nerve neuroanatomic similarities have not been examined. We compared sciatic nerve structural organization in mouse strains (C57BL/6J, DBA/2J, and B6129PF2/J) and rat strains (Wistar, Brown Norway, and Sprague–Dawley). Dissection and retrograde labeling showed mouse sciatic nerve origins predominantly from the third lumbar (L3) and L4 spinal nerves, unlike the L4 and L5 in rats. Proportionate contributions by each level differed significantly between strains in both mice and rats. Whereas all rats had six lumbar vertebrae, variable patterns in mice included mostly five vertebrae in DBA/2J, mostly six vertebrae in C57BL/6J, and a mix in B6129PF2/J. Mice with a short lumbar vertebral column showed a rostral shift in relative contributions to the sciatic nerve by L3 and L4. Ligation of the mouse L4 nerve created hyperalgesia similar to that in rats after L5 ligation, and motor changes were similar after mouse L4 and rat L5 ligation (foot cupping) and after mouse L3 and rat L4 ligation (flexion weakness). Thus, mouse L3 and L4 neural segments are anatomically and functionally homologous with rat L4 and L5 segments. Neuronal changes after distal injury or inflammation should be sought in the mouse L3 and L4 ganglia, and the spinal nerve ligation model in mice should involve ligation of the L4 nerve while L3 remains intact. Strain-dependent variability in segmental contributions to the sciatic nerve may account in part for genetic differences in pain behavior after spinal nerve ligation. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
47. Effect of eugenol on animal models of nociception.
- Author
-
Kurian, R., Arulmozhi, D. K., Veeranjaneyulu, A., and Bodhankar, S. L.
- Subjects
- *
ANALGESICS , *PHARMACOLOGY , *NOCICEPTORS , *HYPERALGESIA , *ACETIC acid , *RATS - Abstract
Objective: To investigate the antinociceptive potential of eugenol on different pain models in mice. Materials and Methods: Eugenol was evaluated (1–100 mg/kg, i.p.) in various experimentally induced pain models like, formalin induced hyperalgesia, acetic acid induced abdominal constrictions, and thermal pain experiment using Eddy's hot plate. Results: Eugenol significantly inhibited acetic acid induced abdominal constrictions, with the maximal effect (92.73% inhibition) at 100 mg/kg. In formalin induced paw licking pain model, eugenol exhibited more pronounced antinociceptive effect in the inflammatory phase than the neurogenic phase (maximal effect was 70.33% and 42.22%, respectively, at 100 mg/kg, i.p). A mild reduction in the pain response latency at 100 mg/kg, i.p. dose of eugenol was observed in the hotplate thermal pain studies in mice. In the rotarod motor coordination experiment eugenol reduced the endurance time at the dose of 100 mg/kg, i.p. Conclusion: The data suggest that eugenol exerts antinociceptive activity in different experimental models of pain in mice. [ABSTRACT FROM AUTHOR]
- Published
- 2006
48. Polysaccharide peptides from COV-1 strain of Coriolus versicolor induce hyperalgesia via inflammatory mediator release in the mouse
- Author
-
Chan, Siu-Lung and Yeung, John H.K.
- Subjects
- *
POLYSACCHARIDES , *PEPTIDES , *CORIOLUS , *HYPERALGESIA - Abstract
Abstract: Polysaccharide peptide (PSP), isolated from Coriolus versicolor COV-1, has been widely used as an adjunct to cancer chemotherapy and as an immuno-stimulator in China. In this study, the anti-nociceptive effects of PSP were investigated in two different pain models in the mouse. In the acetic acid-induced writhing model, initial studies showed that PSP decreased the number of acetic acid-induced writhing by 92.9%, which, by definition, would constitute an analgesic effect. However, further studies showed that PSP itself induced a dose-dependent writhing response. Studies on inflammatory mediator release showed that PSP increased the release of prostaglandin E2, tumor necrosis factor-α, interleukin-1β, and histamine in mouse peritoneal macrophages and mast cells both in vitro and in vivo. The role of inflammatory mediator release in PSP-induced writhing was confirmed when diclofenac and dexamethasone decreased the number of writhing responses by 54% and 58.5%, respectively. Diphenhydramine totally inhibited the PSP-induced writhing. In the hot-plate test, PSP dose-dependently shortened the hind paw withdrawal latency, indicative of a hyperalgesic effect. The hyperalgesic effect was reduced by pretreatment with the anti-inflammatory drugs. In conclusion, the PSP-induced hyperalgesia was related to activation of peritoneal resident cells and an increase in the release of inflammatory mediators. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
49. Behavioral phenotype of pre-proenkephalin-deficient mice on diverse congenic backgrounds.
- Author
-
Bilkei-Gorzo, Andras, Racz, Ildiko, Michel, Kerstin, Zimmer, Anne, Klingmüller, Dietrich, and Zimmer, Andreas
- Subjects
- *
PHENOTYPES , *GENETICS , *ANXIETY , *DIAZEPAM , *DRUGS - Abstract
Rationale: The phenotype of genetically modified animals is thought to result from an interaction of gene manipulation with the genetic background and environmental factors. Objectives: To test the behavioral and drug responses of Penk1-/- mice on different genetic backgrounds. Methods: Congenic C57BL/6J and DBA/2J mouse strains with a targeted deletion of the Penk1 gene were generated. Behavior and drug effects were tested in models of pain and anxiety. Results: Penk1-/- mice showed exaggerated responses to painful or threatening environmental stimuli, but the expressivity of the mutant phenotype was strongly dependent on the behavioral paradigm and on the genetic background. For example, elevated levels of anxiety were readily detectable in C57BL/6J-Penk1-/- mice in the light--dark and startle response tests, but not in the social interaction test. In contrast, we found elevated levels of anxiety in DBA/2J-Penk1-/- mice only in the zero-maze and social interaction tests. In some cases, the idiosyncratic behavior masked the appearance of the knockout gene effect. The activity of the anxiogenic drug, m-chlorophenylpiperazine, but not the anxiolytic drug diazepam, was strain and genotype dependent. Mice with the Penk1 mutation on the DBA/2J, but not on other genetic backgrounds, showed an increased opioid-dependent stress-induced analgesia. Conclusions: (1) The behavioral effects of the Penk1 gene deletion persists on different genetic backgrounds, but its detection sometimes requires the use of different behavioral paradigms. (2) The behavior of the background strain should be considered in the analysis of knockout mice to avoid floor and ceiling effects, which may mask the phenotype. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
50. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia
- Author
-
Mikael A. Kowal, Erik Olofsen, Albert Dahan, Monique van Velzen, Marieke Niesters, and Tine van de Donk
- Subjects
Male ,Time Factors ,Fibromyalgia ,Chronic pain ,0302 clinical medicine ,030202 anesthesiology ,Surveys and Questionnaires ,Cannabidiol ,Dronabinol ,Pain Measurement ,Analgesics ,Cross-Over Studies ,Inhalation ,biology ,Middle Aged ,humanities ,Neurology ,Anesthesia ,CBD ,Female ,medicine.drug ,Research Paper ,musculoskeletal diseases ,Adult ,THC ,Analgesic ,Placebo ,Pain models ,03 medical and health sciences ,Young Adult ,mental disorders ,medicine ,Humans ,Pharmacokinetics ,Aged ,Cannabis ,business.industry ,Placebo cannabis ,organic chemicals ,medicine.disease ,biology.organism_classification ,Crossover study ,nervous system diseases ,Anesthesiology and Pain Medicine ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
Supplemental Digital Content is Available in the Text. This experimental highly controlled trial in 20 patients with fibromyalgia shows that the cannabinoid THC, but not CBD, is effective in the treatment of fibromyalgia pain., In this experimental randomized placebo-controlled 4-way crossover trial, we explored the analgesic effects of inhaled pharmaceutical-grade cannabis in 20 chronic pain patients with fibromyalgia. We tested 4 different cannabis varieties with exact knowledge on their ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) content: Bedrocan (22.4-mg THC
- Published
- 2019
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.